COVID-19 amplified burdens for sponsors, CROs and sites, but especially for participants who faced increased costs and questions around getting to the clinic.
The clinical trial industry responded swiftly, adapting to the global shutdown with bold new ways to conduct trials. Automation has been key to success.
In fact, 84% of sponsors and CROs are actively seeking to increase the use of technology to better support decentralized trials.
When the catalyst of the pandemic wanes, we risk losing the progress we have made unless we collectively refuse to go back to the way things were before - and instead dedicate ourselves to implementing even more advancements and innovations that we've only dreamed of so far.
- Why eClinical technology tools are crucial to delivering on patient and site centricity
- How integraing eCOA and payments can increase retention and improve compliance – the sponsor perspective
- What the considerations are for global implementation and localized requirements
Start planning for the future of clinical trial conduct now to ensure that trials remain efficient, fast, reliable, and trusted. There is #NoGoingBack.